A scientific study conducted by Professor Poulas Konstantinos and his team from the Department of Pharmacy at the University of Patras in Greece, and in collaboration with GemmaCert, a market leader for cannabis analytics, have revealed the results of a scientific study which points toward a significant deviation between labelled and measured cannabidiol (CBD) potency on commercially available products. These results raise safety and efficacy concerns.
Multiple products, legally available on the Greek market, from seven companies were analysed using the industry gold standard for testing cannabis potency, High Performance Liquid Chromatography (HPLC), and GemmaCert‘s cannabis potency testing solution based on its patented technology combining near-infrared spectroscopy, image analysis and advanced data analytics.
Calculations from both devices show that on average product labels understated CBD levels by 50.8%. Results from 206 tests also confirm a close correlation between HPLC and GemmaCert performance with an average variance of 9.63% between the two analytical methods of estimation.
The findings will be presented at the 20th International Congress of the International Society for Ethnopharmacology to be held in Thessaloniki, Greece, in April 2020.
*Article first appeared on the Health Europa Publication.